

Takeovers Code Disclosures

1. 2019 Pescado Loan

On 1 April 2019, the Company entered into a convertible loan note agreement with Pescado Holdings Limited (Pescado) pursuant to which Pescado agreed to advance up to \$4 million to the Company via a new convertible loan note facility (the 2019 Pescado Loan).

On 17 May 2019, the Company's shareholders approved the issue of up to 2,000,000,000 ordinary shares in the Company to Pescado on conversion of the convertible loan notes issued under the 2019 Pescado Loan (the Approved Pescado Allotment Package) in accordance with the takeovers code set out in the schedule to the Takeovers Regulations 2000 (the Takeovers Code). The last date on which such ordinary shares in the Company may be allotted on conversion of such convertible loan notes is 31 March 2021 (which is more than 12 months from the date of the meeting at which the shareholders approved the Approved Pescado Allotment Package). Therefore, and pursuant to rule 19B(2) of the Takeovers Code, the Company is required to include the following information relating to the Approved Pescado Allotment Package in this annual report:



Rule Information required

19B(2)(a) A summary of the terms of the Approved Pescado Allotment Package

The convertible loan notes to be issued under the 2019 Pescado Loan are convertible at \$0.002 per share. On that basis, if the 2019 Pescado Loan is fully drawn from Pescado to the maximum of \$4 million, then the convertible loan notes issued by the Company under the 2019 Pescado Loan could be converted into a maximum of 2,000,000,000 ordinary shares in the Company.

Interest on the 2019 Pescado Loan is nil prior to an event of default, and 9.95% per annum while an event of default is subsisting. Accrued and unpaid interest is payable in cash and does not convert to ordinary shares in the Company.

Pescado has the option to convert all outstanding amounts advanced by it under the 2019 Pescado Loan to ordinary shares in the Company for so long as the 2019 Pescado Loan remains unpaid by the Company.

The Company may repay its indebtedness under the 2019 Pescado Loan at any time in full. However, all payments under the 2019 Pescado Loan must be made pari passu with payments under the Convertible Loan Note Agreement (as defined below).

Unless previously repaid or converted, the 2019 Pescado Loan will mature at 5:00 p.m. on 31 March 2021. On maturity, unless the Company is in default under the 2019 Pescado Loan or insolvent, the outstanding amount under the 2019 Pescado Loan will automatically convert into ordinary shares in the Company at \$0.002 per share.

Shares issued on conversion of the convertible loan notes issued under the 2019 Pescado Loan will be ordinary shares in the Company and will rank equally with all other ordinary shares on issue.

All indebtedness under the 2019 Pescado Loan is secured over all of the assets of the Company and its subsidiaries, in each case under existing security arrangements (which secure indebtedness under the Existing Loans (as defined below)).

Until the 2019 Pescado Loan is repaid in full or converted, the Company will be required to obtain the prior written approval of Pescado to the appointment, replacement or removal of any member of the senior management of the Company or any of its subsidiaries and the appointment by the board of the Company or any person as a director of the Company or any of its subsidiaries.

If Comvita has at any time exercised its contractual right (if any) to appoint a director to the board of the Company who is not Mark Sadd or to remove or replace Mark Sadd as a director on the board of the Company, then drawdown under the 2019 Pescado Loan is conditional on the Company procuring that the board of the Company appoints an individual nominated by Pescado as a director of the Company.

19B(2)(b) Particulars, as at the end of the current financial year, of:

Par	Particulars, as at the end of the current financial year, of:				
(i)	the number of voting securities already allotted to Pescado under the Approved Pescado Allotment Package; and	Nil			
(ii)	the number of voting securities on issue that are held or controlled by Pescado, and the percentage of all voting securities on issue that that number represents; and	855,433,823 ordinary shares (being 17.66% of all voting securities on issue)			
(iii)	the aggregate of the percentages of all voting securities that are held or controlled by Pescado and Pescado's associates; and	17.66% *Note that no associate of Pescado holds any voting securities in the Company.			
(iv)	the maximum percentage of all voting securities that could be held or controlled by Pescado on completion of all the allotments; and	39.33% (being 3,764,524,732 ordinary shares)			
(v)	the maximum aggregate of the percentages of all voting securities that could be held or controlled by Pescado and Pescado's associates on completion of the allotments; and	Same as (iv) above. *Note that no associate of Pescado holds any voting securities in the Company.			
(vi)	the assumptions on which the particulars above are calculated.	In relation to (iv) and (v) above: Pescado is allotted the approved maximum number			

of ordinary shares under the Approved Pescado

the Existing Loans are converted into voting securities in the Company (i.e. ordinary shares); and

the Comvita Option (as defined below) is not

Allotment Package;

exercised



2. Convertible Loan Note Agreement

Pescado, Comvita, One Funds Management Limited as trustee of Asia Pacific Healthcare Fund II (OFM), BioScience Managers Ventures Pty Ltd as general partner of BioScience Management Partnership LP (BMV and, together with OFM, BioScience and, together with Pescado and Comvita, the Existing Noteholders) and the Company entered into an amended and restated convertible loan note agreement (second amendment and restatement) originally dated 30 May 2016, as amended and restated as of 30 June 2018, and further amended and restated on 8 August 2018 (the Convertible Loan Note Agreement). Pursuant to the Convertible Loan Note Agreement:

- a. Pescado agreed to provide convertible loan note facilities to the Company of up to \$3 million, of which the full \$3 million has been advanced;
- b. BioScience agreed to provide convertible loan note facilities to the Company of up to \$3 million, of which the full \$3 million has been advanced; and
- c. Comvita agreed to provide convertible loan note facilities to the Company of up to \$3 million, of which the full \$3 million has been advanced.

together the Existing Loans.

On 8 August 2018, the Company's shareholders approved the issue of up to 909,090,909 ordinary shares in the Company to each Existing Noteholder on conversion of the convertible loan notes issued under the Convertible Loan Note Agreement (the Approved CLN Allotment Package) in accordance with the Takeovers Code. The last date on which such ordinary shares in the Company may be allotted on conversion of such convertible loan notes is 31 March 2020 (which is more than 12 months from the date of the meeting at which the shareholders approved the Approved CLN Allotment Package). Therefore, and pursuant to rule 19B(2) of the Takeovers Code, the Company is required to include the following information relating to the Approved CLN Allotment Package in this annual report:

Rule Information required

19B(2)(a)

A summary of the terms of the Approved CLN Allotment Package

The convertible loan notes that have been issued under the Existing Loans to each Existing Noteholder are convertible at \$0.0033 per share. On that basis, the convertible loan notes issued by the Company under the Convertible Loan Note Agreement could be converted into a maximum of 909,090,909 ordinary shares in the Company for each Existing Noteholder.

Each Existing Noteholder has waived its right to receive interest under the Existing Loans in respect of the period on and from 1 April 2019.

Each Existing Noteholder has the option to convert all outstanding amounts advanced by it under the Existing Loans to ordinary shares in the Company for so long as the relevant Existing Loan remains unpaid by the Company.

The Company may repay its indebtedness under the Existing Loans at any time in full. However, all payments under the Existing Loans must be made pari passu with payments under the 2019 Pescado Loan.

Unless previously repaid or converted, the Existing Loans will mature at 5:00 p.m. on 31 March 2020. On maturity, unless the Company is in default under the Existing Loans or insolvent, the outstanding amount under the Existing Loans will automatically convert into ordinary shares in the Company at \$0.0033 per share.

Shares issued on conversion of the convertible loan notes issued under the Existing Loans will be ordinary shares in the Company and will rank equally with all other ordinary shares on issue.

All indebtedness under the Existing Loans is secured over all of the assets of the Company and its subsidiaries.



19B(2)(b)	Part	iculars, as at the end of the current financial ye	ear, of:
	(i)	the number of voting securities already allotted to each Existing Noteholder under the Approved CLN Allotment Package; and	Pescado – Nil
			BioScience - Nil
			Comvita – Nil
	(ii)	the number of voting securities on issue that are held or controlled by each Existing Noteholder, and the percentage of all voting securities on issue that each of those numbers represents; and	Pescado – 855,433,823 ordinary shares (being 17.66% of all voting securities on issue)
			BioScience – 735,264,802 ordinary shares (being 15.18% of all voting securities on issue)
			Comvita – 410,987,830 ordinary shares (being 8.49% of all voting securities on issue)
	(iii)	i) the aggregate of the percentages of all voting securities that are held or controlled by each Existing Noteholder and its associates; and	Pescado – 17.66%
			BioScience – 15.18%
			Comvita – 8.49%
			*Note that no associate of an Existing Noteholder holds any voting securities in the Company.
	(iv)	the maximum percentage of all voting securities that could be held or controlled by each Existing Noteholder on completion of all the allotments; and	Pescado – 39.33% (being 3,764,524,732 ordinary shares) BioScience – 17.18% (being 1,644,355,711 ordinary shares) Comvita – 13.79% (being 1,320,078,739 ordinary shares)
	(v)	the maximum aggregate of the percentages	Same as (iv) above.
		of all voting securities that could be held or controlled by each Existing Noteholder and its associates on completion of the allotments; and	*Note that no associate of an Existing Noteholder holds any voting securities in the Company.
	(vi)	the assumptions on which the particulars	In relation to (iv) and (v) above:
		above are calculated.	 Pescado is allotted the approved maximum number of ordinary shares under the Approved Pescado Allotment Package;
			• the Existing Loans are converted into voting securities in the Company (i.e. ordinary shares); and
			• the Comvita Option (as defined below) is not exercised.



3. Comvita Option

With effect on and from 8 August 2018, the Company's shareholders approved the Company granting Comvita an option to subscribe for 909,090,909 ordinary shares in the Company at an exercise price of \$0.0033 per share (for an aggregate exercise price of \$3 million) (the Approved Comvita Option Allotment Package) in accordance with the Takeovers Code. The last date on which such ordinary shares may be allotted on conversion of such option is 31 March 2020 (which is more than 12 months from the date of the meeting at which the shareholders approved the Approved Comvita Option Allotment Package). Therefore, and pursuant to rule 19B(2) of the Takeovers Code, the Company is required to include the following information relating to the Approved Comvita Option Allotment Package in this annual report:

Rule	Information required			
19B(2)(a)	A summary of the terms of the Approved Comvita Option Allotment Package			
	The Comvita Option provides Comvita with the option to subscribe for 909,090,909 ordinary shares in the Company at an exercise price of \$0.0033 per share.			
	Any ordinary shares in the Company allotted to Comvita in accordance with the Comvita Option will rank equally with all other ordinary shares on issue.			
	The Comvita Option must be exercised on or before 5:00 p.m. on 31 March 2020. If the Comvita Option is not exercised on or prior to this date, it shall automatically terminate and lapse.			
	The Comvita Option can only be exercised once and only in respect of all and not some only of the ordinary shares.			
	The terms of the Comvita Option include certain mandatory exercise conditions which, if met, would require Comvita to exercise the Comvita Option.			
19B(2)(b)	Particulars, as at the end of the current financial year, of:			
	(i)	the number of voting securities already allotted to Comvita under the Approved Comvita Option Allotment Package; and	Nil	
	(ii)	the number of voting securities on issue that are held or controlled by Comvita, and the percentage of all voting securities on issue that that number represents; and	410,987,830 ordinary shares (being 8.49% of all voting securities on issue)	
	(iii)	the aggregate of the percentages of all voting securities that are held or controlled by Comvita and Comvita's associates; and	8.49% *Note that no associate of Comvita holds any voting securities in the Company.	
	(iv)	the maximum percentage of all voting securities that could be held or controlled by Comvita on completion of all the allotments; and	21.27% (being 2,229,169,648 ordinary shares)	
	(v)	the maximum aggregate of the percentages of all voting securities that could be held or controlled by Comvita and Comvita's associates on completion of the allotments; and	Same as (iv) above. * Note that no associate of Comvita holds any voting securities in the Company.	
	(vi)		In relation to (iv) and (v) above:	
		above are calculated.	 Pescado is allotted the approved maximum number of ordinary shares under the Approved Pescado Allotment Package; and 	
			 the Existing Loans are converted into voting securities in the Company (i.e., ordinary shares); and 	
	· · · · · · · · · · · · · · · · · · ·		the Comvita Option is exercised.	